Company: DVAX
Filing Date: 2025-04-03
Form Type: PREC14A
Source: 0000930413-25-001153
Chunk: 63

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-04-03
Form: PREC14A
Chunk 63
---
 in total market share growth over the year, increasing HEPLISAV-B share of the total U.S. adult market to approximately 44%, compared to approximately 42% at the end of 2023, and demonstrated progress towards achieving our goal of 60% market share by 2030.                                                                                                                                                                                                                              |
| • | HEPLISAV-B market share gains, coupled with hepatitis B market expansion, drove HEPLISAV-B net product revenue to $268.4 million, representing a 26% increase compared to 2023 and another all-time high for the brand.                                                                                                                                                                                                                                                                                              |

| 44 |

Advance our Differentiated Vaccine Pipeline Programs into Clinical Trial Initiations and Data Readouts

| • | Our shingles vaccine program, Z-1018, is an investigational vaccine candidate being developed for the prevention of shingles                 
 in adults aged 50 and older. Enrollment in the Phase 1/2 randomized, active-controlled, dose escalation, multicenter trial was completed     
 in 2024, with approximately 440 healthy adults aged 50 to 69 years enrolled at trial sites in Australia. The trial will evaluate             
 the safety, tolerability, and immunogenicity of Z-1018 compared to Shingrix. Key objectives of the trial include selecting the optimal       
 glycoprotein E (gE) protein dose level and dosing schedule for further clinical development. We anticipate reporting top line immunogenicity 
 and safety data in the third quarter of 2025.                                                                                                |
| • | We are developing a plague (rF1V) vaccine candidate adjuvanted with CpG 1018 adjuvant, in collaboration with, and fully funded               
 by, the U.S. Department of Defense (“DoD”). In late 2024, we completed a Phase 2 clinical trial evaluating the immunogenicity,               
 safety, and tolerability in adults of a plague (rF1V) vaccine candidate adjuvanted with CpG 1018. Based on the results from that             
 study, we executed a new agreement with the DoD for approximately $30.0 million through the first half of 2027 to support additional         
 Phase 2 clinical and manufacturing activities.                                                                                               |

Identify Strategic Opportunities to Accelerate Growth, While Maintaining a Disciplined and Balanced Approach to Capital Allocation

| • | Acceleration of Growth, Disciplined Allocation of Capital |

| • | As noted above, during 2024 we refined our sales approach to